Replies to post #20134 on Synaptogenix Inc (SNPX)

[runncoach]

Almost 250 million the 1st time

[Cyosol]

Investors back then only had the P2a and CU data. Current valuation includes data from both P2b trials.

Good luck finding buyers at a 250 million market cap when the last trial showed placebo outperforming the drug.